MedicalResearch.com Interview with:
Terra G Arnason, MD PhD, Associate Professor,
Division of Endocrinology,
Department of Medicine
University of Saskatchewan
Saskatoon, SK, Canada
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Response: Metformin has been used worldwide for decades to treat Type diabetes.
Metformin is a cheap non-toxic compound that was originally plant derived. In the past decade a number of meta-analyses have demonstrated that Type 2 individuals taking
metformin have a reduced risk of developing many different cancers and do better
longterm. The molecular events facilitating metformin’s activity remain obscure and
it is unknown whether metformin can help cancer patients avoid the development of
drug resistant cancers years after successful treatment.
In our study we asked whether metformin can not only restore sensitivity of multiple drug resistant tumors to chemotherapy once again, but whether metformin can prevent the development of multiple drug resistance in the “rst place. We demonstrate that metformin can sensitize drug resistant cells to chemotherapy once again, which supports recent
studies, but we also show for the “first time that Metformin can prevent the
progression of cancer cells towards drug resistance using cell culture experiments.